Skip to content

Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again

      1. Belgium /
      2. Our innovation /
      3. Focus areas /
      4. Immunology

      Immunology

      Inspired by the promise of helping patients reclaim their lives, we strive to deliver transformational and accessible therapies for patients with conditions in rheumatology, dermatology and gastroenterology.
      commitment to patients.jpeg
      Our commitment to patients
      Johnson & Johnson is committed to alleviating the lifelong challenges faced by those with immune-mediated inflammatory diseases.

      Our goal is to improve the diagnosis of immune-mediated inflammatory diseases, improve patients’ access to the best possible treatments and continue to provide new and better medicines.
      immune-mediated inflammatory diseases.webp
      We recognize the profound impact of Immune-Mediated Diseases
      People living with immune-mediated inflammatory diseases can be affected for the rest of their lives, yet the impact of these conditions is dramatically underestimated. As some of these diseases are not readily recognised, people can suffer silently before eventually receiving treatment.
      Our mission is clear: we won’t rest until we achieve a world free from immune-mediated inflammatory diseases.
      Our treatment areas
      We are proud to have one of the strongest treatment portfolios for some of the most common immune-mediated inflammatory diseases.
      derma.webp
      Dermatology
      Our focus in dermatology is on the inflammatory skin condition psoriasis.
      rheuma.webp
      Rheumatology
      Our focus in Rheumatology is currently inflammatory disorders of the joints and skin: Psoriatic Arthritis, Rheumatoid Arthritis (RA) and Axial Spondyloarthritis (AxSpA).
      gastro.webp
      Gastroenterology
      Our focus in Gastroenterology is inflammatory bowel disease: Crohn’s disease and Ulcerative colitis.
      breakthroughs .webp
      Our pioneering breakthroughs change lives
      We’ve always been innovative in our science, finding new and more effective ways to transform the course of immune-mediated inflammatory diseases and calm the inner battle waging within patients’ bodies.

      Since the advent of targeted biologic therapy over 35 years ago, we developed the first licensed monoclonal antibody to act directly on the immune system, providing patients with an unprecedented level of efficacy and symptomatic relief.1
      Our breakthroughs have changed the lives of millions of people around the world living with some of the most common immune-mediated inflammatory diseases.
      search for newer and better medicines.webp
      We will continue our search for more advanced and effective medicines
      We remain committed to developing better therapies with the goal of stopping or even curing immune-mediated inflammatory diseases, especially where significant unmet needs persist.
      Our commitment to immune-mediated inflammatory diseases goes beyond our medicines. We support patients through collaborations with patient advocacy organisations.

      We invest heavily in continuous medical education of doctors and care providers, uniting different therapeutic areas to share expertise and best practices.
      We also bring together the brightest minds, including doctors, nurses, patients and patient groups, scientists and policy makers to turn scientific discoveries into treatment breakthroughs, and to ensure that people can benefit from the best treatments when they need them.
      Even though we have made great progress in the last decade for the treatment of immune-mediated inflammatory diseases, our work aims to raise the bar to make periods of disease remission more durable and allow patients with these debilitating diseases to lead normal lives.
      Ludovic de Beaucoudrey, PhD
      JANSSEN THERAPEUTIC AREA LEAD, IMMUNOLOGY, EUROPE, MIDDLE EAST & AFRICA
      If you want to learn more about psoriasis or psoriatic arthritis, check out Apsolutely, our online patient portal for people living with psoriatic disease or who are interested in learning more about the disease.

      References

      [1] Liu JK. The history of monoclonal antibody development - Progress, remaining challenges and future innovations. Ann Med Surg (Lond). 2014;3(4):113-116

      © Janssen-Cilag NV/B.V., a Johnson&Johnson company – CP-490851 – Approval date: 11-2024, vu/er Luc Van Oevelen, Antwerpseweg 15-17, 2340 Beerse